Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials. Issue 3 (21st November 2018)

• Record Type: Journal Article
• Authors: Matralis, Alexios N.; Afantitis, Antreas; Aidinis, Vassilis
• Is Part Of: Medicinal research reviews. Volume 39:Issue 3(2019)
• Page Start: 976
• Page End: 1013
• Publication Date: 2018-11-21
• Subjects: autotaxin -- autotaxin inhibitors -- drug design and development -- lysophosphatidic acid -- lysophosphatidylcholine -- medicinal chemistry; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21551
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: Several years after its isolation from melanoma cells, an increasing body of experimental evidence has established the involvement of Autotaxin (ATX) in the pathogenesis of several diseases. ATX, an extracellular enzyme responsible for the hydrolysis of lysophosphatidylcholine (LPC) into the bioactive lipid lysophosphatidic acid (LPA), is overexpressed in a variety of human metastatic cancers and is strongly implicated in chronic inflammation and liver toxicity, fibrotic diseases, and thrombosis. Accordingly, the ATX‐LPA signaling pathway is considered a tractable target for therapeutic intervention substantiated by the multitude of research campaigns that have been successful in identifying ATX inhibitors by both academia and industry. Furthermore, from a therapeutic standpoint, the entry and the so far promising results of the first ATX inhibitor in advanced clinical trials against idiopathic pulmonary fibrosis (IPF) lends support to the viability of this approach, bringing it to the forefront of drug discovery efforts. The present review article aims to provide a comprehensive overview of the most important series of ATX inhibitors developed so far. Special weight is lent to the design, structure activity relationship and mode of binding studies carried out, leading to the identification of advanced leads. The most significant in vitro and in vivo pharmacological results of these advanced leads are also summarized. Lastly, the development of the first ATX inhibitor entered in clinical trials accompanied by its phase 1 and 2a clinical trial data is disclosed.